Let's talk AI: Top R&D execs tackle where we are and where we're headed with this crucial new technology
As a biotech exec with a background in computational chemistry, Rosana Kapeller has been watching the hubbub over artificial intelligence and machine learning in biopharma play out with a considerable degree of skepticism.
“People talk about ML and AI without knowing what they are talking about,” the outspoken Nimbus alum told me earlier in the week. And there are some big pitfalls the uninitiated are likely to drop into without warning if they follow the crowd into AI without thinking things through first.
Now at Google’s GV as an entrepreneur-in-residence taking a specialist approach to computational technologies, Kapeller has a lot of respect for Stanford AI star Daphne Koller, who’s dived into the complex task of drawing her own map to follow when it comes to using AI in R&D. And she wonders where others without Koller’s background will wind up if they start using AI and ML in particular fields where the data are lacking.
That’s the backdrop to a conversation I’ve long looked forward to.
Next Tuesday in Philadelphia during the annual BIO confab, Kapeller and a number of top execs from some of the biggest players in the industry will join me to discuss how they’re using AI and ML right now. In every case, these are largely new efforts where biopharmas are looking to this technology to improve their odds of success — which I think most everyone in R&D would agree are pretty poor. And contrary to what you may assume, there’s a very practical attitude about what they can do and what they can’t, and how they believe this field will evolve over the next 4-5 years.
The rest of the lineup for next week’s discussion looks like this: GSK’s Tony Wood, Saurabh Saha at Bristol-Myers Squibb, Hugo Ceulemans from J&J, Badhri Srinivasan at Novartis and Shoibal Datta, a Biogen vet now at PPD.
I hope you can join us for this event and contribute your own thoughts and questions. You can get tickets here.
Image: John Carroll